The PCSK9 trials have confirmed (a) the absence of a J-point curve for LDL-C lowering and (b) continuing CV risk reduction, even when lowering LDL-C from 100mg/dL to 30mg/dL. In light of this, how should the lipid specialist deploy PCSK9 inhibitors?
The PCSK9 trials have confirmed (a) the absence of a J-point curve for LDL-C lowering and (b) continuing CV risk reduction, even when lowering LDL-C from 100 mg/dL to 30 mg/dL. In light of this, how should the lipid specialist deploy PCSK9 inhibitors?
Created by
Presenter
Michael Davidson, MD, FACC, FACP, FNLA
Clinical Professor Director of Preventive Cardiology The University of Chicago Hospitals and Clinic Pritzker School of Medicine Chicago, Illinois